Cholestech begins US delivery of liver enzyme test:
This article was originally published in Clinica
Hayward, California-based diagnostics developer Cholestech has begun shipping in the US its Aspartate Aminotransferase (AST) test for assessing damage to the liver due to drugs or certain diseases. The assay, the only CLIA-waivered one of its kind, runs on Cholestech's LDX system in conjunction with its other liver enzyme test, Alanine Aminotransferase (ALT). Nearly 200 million ALT and AST tests are ordered in the US each year, says Cholestech.
You may also be interested in...
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.
Consumer health product firms say the coronavirus will have an impact on their results, but it’s too early to estimate the costs. US FDA also hedges its predictions, saying the outbreak could lead to interruptions in country’s drug and medical device supplies. China's health commission has issued six guidelines for diagnosis and treatment, but no conventional antiviral treatment is approved and it's emphasizing traditional Chinese medicines.
With less than one hundred days left before the European Union Medical Device Regulations kick in, Medtech Insight’s executive editor Ashley Yeo and managing editor Amanda Maxwell discuss growing concerns by medtech industry members that they may not be ready in time to comply with these regulations and may inadvertently go afoul of the new regulations.